Skip to main content
Top
Published in: Acta Diabetologica 4/2009

01-12-2009 | Original Article

Variants of the adiponectin gene and type 2 diabetes in a Polish population

Authors: Magdalena Szopa, Malgorzata Malczewska-Malec, Beata Wilk, Jan Skupien, Pawel Wolkow, Maciej T. Malecki, Jacek Sieradzki

Published in: Acta Diabetologica | Issue 4/2009

Login to get access

Abstract

Several association studies of type 2 diabetes mellitus (T2DM) and adiponectin gene polymorphisms have been reported with conflicting results. Our aim was to search for the association of three polymorphisms (−11.391G>A, +45T>G, and +276G>T) in the adiponectin gene with T2DM and prediabetic quantitative traits in Polish Caucasians. The study groups comprised 495 unrelated T2DM cases and 435 controls. We compared the distribution of genotypes between study groups. In addition, genotype-quantitative trait analyses were also done in the controls. The study subjects were genotyped using the restriction fragment length polymorphism technique. The frequencies of the minor alleles were as follows: 10.6 versus 8.2% for −11.391G>A (p = 0.0722), 7.0 versus 8.0% for +45T>G (p = 0.48), and 15.5% in T2DM versus 19.8% in controls (p = 0.0145) for +276G>T, respectively. The difference for genotype distribution between the groups was statistically significant (p = 0.0247) for the +276G>T variant: 71.31 versus 62.99%, 26.46 versus 34.48% and 2.22 versus 2.53%, respectively, for GG, GT and TT. In quantitative traits analysis, the T allele of +276G>T was associated (p < 0.05) with lower insulin resistance (HOMA-IR, fasting insulin) among controls. Additionally, the A allele at position −11.391 was associated (p < 0.05) with higher insulin resistance (HOMA-IR, fasting insulin). In multiple regression analysis, all identified association remained significant after the inclusion in the model of gender, BMI and age. In addition, in this model, −11.391G>A and +276G>T were independently associated with T2DM. Finally, we conclude that the adiponectin gene polymorphisms are associated with T2DM and prediabetic quantitative traits in Polish Caucasians.
Literature
1.
go back to reference Kronenberg F (2008) Genome-wide association studies in aging-related processes such as diabetes mellitus, atherosclerosis and cancer. Exp Gerontol 43:39–43CrossRefPubMed Kronenberg F (2008) Genome-wide association studies in aging-related processes such as diabetes mellitus, atherosclerosis and cancer. Exp Gerontol 43:39–43CrossRefPubMed
2.
go back to reference Rampersaud E, Damcott CM, Fu M et al (2007) Identification of novel candidate genes for type 2 diabetes from a genome-wide association scan in the old order Amish: evidence for replication from diabetes-related quantitative traits and from independent populations. Diabetes 56:3053–3062CrossRefPubMed Rampersaud E, Damcott CM, Fu M et al (2007) Identification of novel candidate genes for type 2 diabetes from a genome-wide association scan in the old order Amish: evidence for replication from diabetes-related quantitative traits and from independent populations. Diabetes 56:3053–3062CrossRefPubMed
3.
go back to reference Hayes MG, Pluzhnikov A, Miyake K et al (2007) Identification of type 2 diabetes genes in Mexican Americans through genome-wide association studies. Diabetes 56:3033–3044CrossRefPubMed Hayes MG, Pluzhnikov A, Miyake K et al (2007) Identification of type 2 diabetes genes in Mexican Americans through genome-wide association studies. Diabetes 56:3033–3044CrossRefPubMed
4.
go back to reference Luke A, Wu X, Zhu X et al (2003) Linkage for BMI at 3q27 region confirmed in an African–American population. Diabetes 52:1284–1287CrossRefPubMed Luke A, Wu X, Zhu X et al (2003) Linkage for BMI at 3q27 region confirmed in an African–American population. Diabetes 52:1284–1287CrossRefPubMed
5.
go back to reference Berg AH, Combs TP, Du X et al (2001) The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7:947–953CrossRefPubMed Berg AH, Combs TP, Du X et al (2001) The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7:947–953CrossRefPubMed
6.
go back to reference Yamauchi T, Kamon J, Minokoshi Y et al (2002) Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8:1288–1295CrossRefPubMed Yamauchi T, Kamon J, Minokoshi Y et al (2002) Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8:1288–1295CrossRefPubMed
7.
go back to reference Ouchi N, Kihara S, Arita Y et al (2001) Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 103:1057–1063PubMed Ouchi N, Kihara S, Arita Y et al (2001) Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 103:1057–1063PubMed
8.
go back to reference Scherer PE, Williams S, Fogliano M et al (1995) A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 270:26746–26749CrossRefPubMed Scherer PE, Williams S, Fogliano M et al (1995) A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 270:26746–26749CrossRefPubMed
9.
go back to reference Arita Y, Kihara S, Ouchi N et al (1999) Paradoxical decrease of an adipose-specific protein, adiponectin in obesity. Biochem Biophys Res Commun 257:79–83CrossRefPubMed Arita Y, Kihara S, Ouchi N et al (1999) Paradoxical decrease of an adipose-specific protein, adiponectin in obesity. Biochem Biophys Res Commun 257:79–83CrossRefPubMed
10.
go back to reference Yamauchi T, Kamon J, Waki H et al (2001) The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance. J Biol Chem 276:41245–41254CrossRefPubMed Yamauchi T, Kamon J, Waki H et al (2001) The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance. J Biol Chem 276:41245–41254CrossRefPubMed
11.
go back to reference Heid IM, Wagner SA, Gohlke H et al (2006) Genetic architecture of the APM1 gene and its influence on adiponectin plasma levels and parameters of the metabolic syndrome in 1,727 healthy Caucasians. Diabetes 55:375–384CrossRefPubMed Heid IM, Wagner SA, Gohlke H et al (2006) Genetic architecture of the APM1 gene and its influence on adiponectin plasma levels and parameters of the metabolic syndrome in 1,727 healthy Caucasians. Diabetes 55:375–384CrossRefPubMed
12.
go back to reference Tso AW, Sham PC, Wat NM et al (2006) Polymorphisms of the gene encoding adiponectin and glycaemic outcome of Chinese subjects with impaired glucose tolerance: a 5-year follow-up study. Diabetologia 49:1806–1815CrossRefPubMed Tso AW, Sham PC, Wat NM et al (2006) Polymorphisms of the gene encoding adiponectin and glycaemic outcome of Chinese subjects with impaired glucose tolerance: a 5-year follow-up study. Diabetologia 49:1806–1815CrossRefPubMed
13.
go back to reference Sutton BS, Weinert S, Langefeld CD et al (2005) Genetic analysis of adiponectin and obesity in Hispanic families: the IRAS family study. Hum Genet 117:107–118CrossRefPubMed Sutton BS, Weinert S, Langefeld CD et al (2005) Genetic analysis of adiponectin and obesity in Hispanic families: the IRAS family study. Hum Genet 117:107–118CrossRefPubMed
14.
go back to reference Takahashi M, Arita Y, Yamagata K et al (2000) Genomic structure and mutations in adipose-specific gene, adiponectin. Int J Obes Relat Metab Disord 24:861–868CrossRefPubMed Takahashi M, Arita Y, Yamagata K et al (2000) Genomic structure and mutations in adipose-specific gene, adiponectin. Int J Obes Relat Metab Disord 24:861–868CrossRefPubMed
15.
go back to reference Menzaghi C, Trischitta V, Doria A (2007) Genetic influences of adiponectin on insulin resistance, type 2 diabetes and cardiovascular disease. Diabetes 56:1198–1209CrossRefPubMed Menzaghi C, Trischitta V, Doria A (2007) Genetic influences of adiponectin on insulin resistance, type 2 diabetes and cardiovascular disease. Diabetes 56:1198–1209CrossRefPubMed
16.
go back to reference Malecki MT, Frey J, Moczulski D et al (2003) Vitamin D receptor gene polymorphisms and association with type 2 diabetes mellitus in a Polish population. Exp Clin Endocrinol Diabetes 111:505–509CrossRefPubMed Malecki MT, Frey J, Moczulski D et al (2003) Vitamin D receptor gene polymorphisms and association with type 2 diabetes mellitus in a Polish population. Exp Clin Endocrinol Diabetes 111:505–509CrossRefPubMed
17.
go back to reference Schwarz PE, Govindarajalu S, Towers W et al (2006) Haplotypes in the promoter region of the ADIPOQ gene are associated with increased diabetes risk in a German Caucasian population. Horm Metab Res 38:447–451CrossRefPubMed Schwarz PE, Govindarajalu S, Towers W et al (2006) Haplotypes in the promoter region of the ADIPOQ gene are associated with increased diabetes risk in a German Caucasian population. Horm Metab Res 38:447–451CrossRefPubMed
18.
go back to reference Vasseur F, Helbecque N, Lobbens S et al (2005) Hypoadiponectinaemia and high risk of type 2 diabetes are associated with adiponectin-encoding (ACDC) gene promoter variants in morbid obesity: evidence for a role of ACDC in diabesity. Diabetologia 48:892–899CrossRefPubMed Vasseur F, Helbecque N, Lobbens S et al (2005) Hypoadiponectinaemia and high risk of type 2 diabetes are associated with adiponectin-encoding (ACDC) gene promoter variants in morbid obesity: evidence for a role of ACDC in diabesity. Diabetologia 48:892–899CrossRefPubMed
19.
go back to reference Vasseur F, Helbecque N, Dina C et al (2002) Single-nucleotide polymorphism haplotypes in the both proximal promoter and exon 3 of the APM1 gene modulate adipocyte-secreted adiponectin hormone levels and contribute to the genetic risk for type 2 diabetes in French Caucasians. Hum Mol Genet 11:2607–2614CrossRefPubMed Vasseur F, Helbecque N, Dina C et al (2002) Single-nucleotide polymorphism haplotypes in the both proximal promoter and exon 3 of the APM1 gene modulate adipocyte-secreted adiponectin hormone levels and contribute to the genetic risk for type 2 diabetes in French Caucasians. Hum Mol Genet 11:2607–2614CrossRefPubMed
20.
go back to reference Gu HF, Abulaiti A, Ostenson CG et al (2004) Single nucleotide polymorphisms in the proximal promoter region of the adiponectin (APM1) gene are associated with type 2 diabetes in Swedish caucasians. Diabetes 53(Suppl 1):S31–S35CrossRefPubMed Gu HF, Abulaiti A, Ostenson CG et al (2004) Single nucleotide polymorphisms in the proximal promoter region of the adiponectin (APM1) gene are associated with type 2 diabetes in Swedish caucasians. Diabetes 53(Suppl 1):S31–S35CrossRefPubMed
21.
go back to reference Populaire C, Mori Y, Dina C et al (2003) Does the –11377 promoter variant of APM1 gene contribute to the genetic risk for type 2 diabetes mellitus in Japanese families? Diabetologia 46:443–445PubMed Populaire C, Mori Y, Dina C et al (2003) Does the –11377 promoter variant of APM1 gene contribute to the genetic risk for type 2 diabetes mellitus in Japanese families? Diabetologia 46:443–445PubMed
22.
go back to reference Gibson F, Froguel P (2004) Genetics of the APM1 locus and its contribution to type 2 diabetes susceptibility in French Caucasians. Diabetes 53:2977–2983CrossRefPubMed Gibson F, Froguel P (2004) Genetics of the APM1 locus and its contribution to type 2 diabetes susceptibility in French Caucasians. Diabetes 53:2977–2983CrossRefPubMed
23.
go back to reference Buzzetti R, Petrone A, Zavarella S et al (2007) The glucose clamp reveals an association between adiponectin gene polymorphisms and insulin sensitivity in obese subjects. Int J Obes (Lond) 31:424–428CrossRef Buzzetti R, Petrone A, Zavarella S et al (2007) The glucose clamp reveals an association between adiponectin gene polymorphisms and insulin sensitivity in obese subjects. Int J Obes (Lond) 31:424–428CrossRef
24.
go back to reference Kita A, Yamasaki H, Kuwahara H et al (2005) Identification of the promoter region required for human adiponectin gene transcription: association with CCAAT/enhancer binding protein-beta and tumor necrosis factor-alpha. Biochem Biophys Res Commun 331:484–490CrossRefPubMed Kita A, Yamasaki H, Kuwahara H et al (2005) Identification of the promoter region required for human adiponectin gene transcription: association with CCAAT/enhancer binding protein-beta and tumor necrosis factor-alpha. Biochem Biophys Res Commun 331:484–490CrossRefPubMed
25.
go back to reference Bouatia-Naji N, Meyre D, Lobbens S et al (2006) ACDC/adiponectin polymorphisms are associated with severe childhood and adult obesity. Diabetes 55:545–550CrossRefPubMed Bouatia-Naji N, Meyre D, Lobbens S et al (2006) ACDC/adiponectin polymorphisms are associated with severe childhood and adult obesity. Diabetes 55:545–550CrossRefPubMed
Metadata
Title
Variants of the adiponectin gene and type 2 diabetes in a Polish population
Authors
Magdalena Szopa
Malgorzata Malczewska-Malec
Beata Wilk
Jan Skupien
Pawel Wolkow
Maciej T. Malecki
Jacek Sieradzki
Publication date
01-12-2009
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 4/2009
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-008-0091-2

Other articles of this Issue 4/2009

Acta Diabetologica 4/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine